Omer Fatih Olmez

7PUBLICATIONS
27CO-AUTHORS
Predictive and prognostic markersModels of care and place of birthMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Sep 27, 2025
The Prognostic Roles of Systemic Inflammatory Markers Before Abiraterone or Enzalutamide Therapy in Metastatic Castration-Resistant Prostate Cancer.

Harun Muğlu, Erdem Sünger, Lamia Şeker Can

|May 14, 2025
Clinical Outcomes in Early-Stage HER2-Low and HER2-Zero Breast Cancer: Single-Center Experience.

Jamshid Hamdard, Mehmet Haluk Yücel, Harun Muğlu

|May 14, 2025
The Clinical Outcomes and Safety of Sacituzumab Govitecan in Heavily Pretreated Metastatic Triple-Negative and HR+/HER2- Breast Cancer: A Multicenter Observational Study from Turkey.

Harun Muğlu, Kaan Helvacı, Bahadır Köylü

|May 01, 2025
The Prognostic and Predictive Roles of Ataxia-Telangiectasia Mutated (ATM) Expression in Patients with Metastatic Non-Small-Cell Lung Cancer Receiving Pembrolizumab Monotherapy Alone or in Combination with Chemotherapy.

Jamshid Hamdard, Harun Muğlu, Ahmet Bilici

|Jan 08, 2025
Association Between Baseline and Changes in Early Neutrophil-to-Lymphocyte Ratio on Survival in Patients with Metastatic Bladder Carcinoma Treated with Immunotherapy.

Ezgi Değerli, Çağatay Arslan, Fatih Selçukbiricik

|Sep 23, 2022
High expression of CD8 in the tumor microenvironment is associated with PD-1 expression and patient survival in high-grade serous ovarian cancer.

Fatma Ölmez, Süleyman Cemil Oğlak, Ömer Fatih Ölmez

Pageof 2

Frequent Collaborators

4 joint publications

Jamshid Hamdard

3 joint publications

Ahmet Bilici

3 joint publications

Özgür Açıkgöz

3 joint publications

Harun Muğlu